MD, PHD
HEAD OF THE GASTROINTESTINAL CANCER PROGRAM
UNIT AT VALL D'HEBRON UNIVERSITY HOSPITAL
BARCELONA, SPAIN
About Our Speaker
Furthermore, she actively participates in Phase I, II, and III studies involving new chemotherapy agents for GI tumors. She is specialized in translational research on hepatobiliopancreatic tumors and targeted therapies, such as epidermal growth factor receptor inhibitors.
Considering both patient and clinician perspective, as well as sequential treatment algorithms, can help give the best treatment option for mPaCa patients.
Real-world evidence highlights the importance of early treatment planning to optimize clinical management of patients with mPaCa.
This webinar focuses on long-term outcomes in CCA achieved with 2L targeted treatments.